ANDA 74292, held by Hospira. Dobutamine Hydrochloride.
As of Nov 16, 2026, ANDA 74292 (Dobutamine Hydrochloride), held by Hospira, was first approved by FDA on Feb 16, 1995, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 16, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dobutamine HydrochlorideEQ 12.5MG BASE/ML ยท injectable;injection | Dobutamine Hydrochloride | Discontinued |
| Feb 14, 2001 | Supplement 8Manufacturing | Approved | None posted |
| Jun 23, 1997 | Supplement 7Labeling | Approved | None posted |
| Jan 28, 1997 | Supplement 5Manufacturing | Approved | None posted |
| Jan 28, 1997 | Supplement 4Manufacturing | Approved | None posted |
| Dec 24, 1996 | Supplement 6Labeling | Approved | None posted |
| Jun 7, 1996 | Supplement 3Manufacturing | Approved | None posted |
| Jun 7, 1996 | Supplement 2Labeling | Approved | None posted |
| Jun 7, 1996 | Supplement 1Manufacturing | Approved | None posted |
| Feb 16, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters